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Abstract 
Objective: To obtain a reliable estimate of the magnitude of the prospective association 
between gamma-glutamyltransferase (GGT) and risk of hypertension, and to characterize the 
nature of the dose-response relationship.  
Methods: We conducted a systematic review and dose-response meta-analysis of published 
prospective studies. Relevant studies were identified in a literature search of MEDLINE, 
EMBASE, and Web of Science databases up to May 2015. Study specific relative risks (RRs) 
were meta-analysed using random effects models. We examined a potential nonlinear 
relationship using restricted cubic splines.   
Results: Of the 612 titles reviewed, we included 14 cohort studies with data on 44,582 
participants and 5,270 hypertension cases. In a comparison of extreme thirds of baseline levels 
of GGT, RR for hypertension in pooled analysis of all 14 studies was 1.32 (95% confidence 
interval: 1.23-1.43). There was heterogeneity among the studies (P < 0.001), which was to a 
large part explained by average age of participants at baseline, average duration of follow-up, 
and the degree of confounder adjustment. In a pooled dose-response analysis of 10 studies with 
relevant data, there was evidence of a linear association between GGT and hypertension risk (P 
for nonlinearity = 0.37). The pooled RR of hypertension per 5 U/L increment in GGT levels was 
1.08 (95% confidence interval: 1.04-1.13).  
Conclusion: Baseline circulating GGT level is associated with an increased risk of hypertension 
in the general population, consistent with a linear dose-response relationship. Further 
investigation of any potential relevance of GGT in hypertension prevention is warranted. 
Keywords: gamma-glutamyltransferase; hypertension; high blood pressure; prospective studies; 
dose-response; meta-analysis 
Abbreviations: BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; GGT, 
gamma-glutamyltransferase; NOS, Newcastle–Ottawa Scale; RR, relative risk; SD, standard 
deviation  
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INTRODUCTION 
Hypertension or high blood pressure (BP) has risen to pandemic proportions - affecting over 1 
billion people worldwide and it has been estimated that this number will reach 1.56 billion by 
2025.[1] In addition to being the leading global risk for mortality in the world,[2] hypertension 
is the most common modifiable and leading risk factor for cardiovascular disease (CVD),[3] 
which represents a worldwide epidemic and is the leading cause of mortality globally.[4] To 
date, established risk factors for hypertension include excess body weight, excess dietary 
sodium intake, reduced physical activity, and excess alcohol intake.[5, 6] In line with the 2013 
guidelines developed by the European Society of Hypertension and the European Society of 
Cardiology (ESH/ESC),[7] lifestyle changes have been recommended as the cornerstone for the 
prevention of hypertension or high BP. These include a combination of population-based and 
intensive targeted approaches such as reduction of salt and alcohol consumption, maintaining a 
healthy body weight, regular exercise, and elimination of smoking.[7] Though established risk 
factors for hypertension explain a large proportion of its risk, its pathogenesis is still not fully 
established as multiple factors appear to be involved. There is therefore a need to further assess 
potential risk factors which may have causal or predictive relevance to hypertension and which 
will help further tailor preventive and therapeutic interventions 
 
Gamma-glutamyltransferase (GGT), a sensitive but non-specific index of liver injury and a 
biological clue of excessive alcohol intake, has been strongly linked to the development of 
adverse cardiometabolic outcomes [8-10] including hypertension.[11] Elevated serum levels of 
GGT has been postulated to reflect the development and progression of hepatic steatosis; which 
may play an important role in the development of insulin resistance and hyperinsulinemia, 
resulting in high blood pressure or hypertension.[12-14] Until recently, there has been 
uncertainty regarding the magnitude and nature of the prospective association between GGT 
level and risk of hypertension. Liu and colleagues[15] synthesized available prospective 
epidemiological data on the association between GGT and hypertension and reported a pooled 
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multivariate adjusted relative risk (RR) (95% confidence interval) of 1.94 (1.55-2.43) for 
hypertension in a comparison of top versus bottom category of baseline GGT levels. However, 
in this review, the authors did not standardize the reported risk estimates (they reported 
comparisons comparing the highest versus lowest category of GGT levels irrespective of the 
risk estimates the eligible studies reported) to a consistent comparison before pooling. In 
addition, they separately pooled the results of three studies that provided risk estimates per 1 
standard deviation (SD) increment in loge GGT levels. Given these, the magnitude of the 
association could not be precisely determined. In addition, although the evidence suggests there 
is a strong association between elevated baseline circulating GGT and risk of incident 
hypertension; characterization of the nature and magnitude of the dose-response relationship is 
however still lacking, as this was not addressed by previous studies and the recent review. It is 
uncertain if there is a clear continuous dose-response relationship to the association or if this 
association is evident only beyond a particular threshold level of GGT. It is important to 
establish this, especially if there exists a threshold which would potentially optimize the 
detection of individuals at increased risk of hypertension. A dose-response analysis is more 
efficient than comparing the highest to lowest category approach, as it uses all of the exposure-
disease information and provides a detailed description of the risk of the disease throughout the 
observed range of the exposure.[16] Against this background, our first objective using a meta-
analytic approach, was to obtain a reliable estimate of the magnitude of the association between 
GGT and hypertension, by including all relevant studies and standardising reported risk 
estimates from all studies to a consistent comparison (top versus bottom thirds of baseline levels 
of GGT) before pooling. Our second objective was to quantify and characterize in detail the 
nature of the dose-response relationship between GGT level and risk of hypertension.  
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METHODS 
Data sources and searches 
This systematic review and meta-analysis of studies was conducted using a predefined protocol 
and reported in accordance with PRISMA and MOOSE guidelines [17, 18] (Supplementary 
Materials 1-2). We searched MEDLINE, EMBASE, and Web of Science for prospective 
(cohort, case-cohort or “nested case control”) population-based studies that measured the level 
of enzymatic activity of GGT and evaluated associations between baseline circulating level of 
GGT with risk of hypertension or high BP up to May 2015. The computer-based searches 
combined free and MeSH search terms and combined key words related to GGT (e.g., “gamma 
glutamyltransferase”) and hypertension (e.g., “hypertension”, “blood pressure”). There were no 
restrictions on language or the publication date. We scanned the reference lists of retrieved 
articles for all relevant additional studies and review articles. We restricted the search to studies 
of humans. Further details on the search strategy are presented in Supplementary Material 3. 
 
Study selection 
Observational cohort studies were included if they had at least 1 year of follow-up, assessed 
associations of GGT with hypertension in adults (>18 years), measured samples at baseline, 
recruited participants representative of approximately general populations (i.e., did not select 
participants on the basis of confirmed pre-existing medical conditions such as hypertension or 
high blood pressure, cardiovascular disease, liver disease, or chronic kidney disease at baseline). 
Retrospective studies were not included. 
 
Data extraction and quality assessment  
Two authors independently abstracted data and performed quality assessments using a 
standardized predesigned data collection form. Data were abstracted, where available, on study, 
publication date, geographical location, population source, time of baseline survey, sample 
population, study design, sample source (plasma/serum), nature of sample (fresh or frozen and 
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storage temperature), assay type and source, sample size, number of hypertension cases, 
hypertension case definition, mean age range at start of study, duration of follow-up, and degree 
of adjustment for potential confounders (defined as ‘+’ when RRs were adjusted for age and/or 
sex; ‘++’ further adjustment for potential risk factors for hypertension such as body mass index, 
plasma or serum lipids, smoking status, exercise, or alcohol consumption; and ‘+++’ additional 
adjustment for other liver enzymes and or inflammatory markers). We extracted RRs reported 
for the greatest degree of adjustment. In the case of multiple publications involving the same 
cohort, the most up-to-date study or study with the most comprehensive information was 
abstracted. We contacted authors of eligible studies where the published data were insufficient, 
to provide relevant missing information. 
 
Study quality was assessed based on the nine-star Newcastle–Ottawa Scale (NOS)[19] using 
pre-defined criteria namely: selection (population representativeness), comparability 
(adjustment for confounders), and ascertainment of outcome. The NOS assigns a maximum of 
four points for selection, two points for comparability, and three points for outcome. Nine points 
on the NOS reflects the highest study quality. A score of ≥ 5 indicated adequate quality for 
inclusion in the review. 
 
Data synthesis and analysis 
The RR with 95% CIs was used as the common measure of association across studies. To 
enable a consistent approach to the meta-analysis and enhance interpretation of the findings, 
reported study-specific risk estimates (per standard deviation change, quintiles, quartiles, and 
user-defined cut-offs) were transformed to involve comparisons between the top third and 
bottom third of each study population’s baseline distribution of GGT levels, using standard 
statistical methods [20, 21] which have been described in detail in Supplementary Material 4. 
Briefly, log risk estimates were transformed assuming a normal distribution (or that a 
transformation of the explanatory variable for which the risk ratio is based was normally 
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distributed), with the comparison between top and bottom thirds being equivalent to 2.18 times 
the log risk ratio for a 1 standard deviation increase (or equivalently, as 2.18/2.54 times the log 
risk ratio for a comparison of extreme quarters and as 2.18/2.80 times the log risk ratio for a 
comparison of extreme quintiles). Standard errors of the log risk estimates were calculated using 
published confidence limits and were standardised in the same way. When studies published 
more than one estimate of the association according to subgroups (e.g., by sex), we obtained a 
within-study summary estimate using a fixed effect meta-analysis. Summary RRs were pooled 
using a random effects model to minimize the effect of between-study heterogeneity.[22]  
 
To avoid making an assumption of linearity for an exposure-response (e.g. GGT-hypertension) 
relation, exposure-response relations are usually reported through RRs corresponding to ranges 
of exposure levels. Therefore, in a meta-analysis, it is useful to model the relation in a flexible 
nonlinear manner and assess evidence for or lack of nonlinearity, using graphical and statistical 
testing procedures.[23] We therefore performed a 2-stage dose-response meta-analysis using the 
method proposed by Orsini,[24] to examine a potential nonlinear relationship between GGT 
levels and hypertension risk by modeling GGT levels using restricted cubic splines with 3 knots 
at percentiles 25%, 50%, and 75% of the distribution.[25] This method requires that the number 
of cases, person-years of follow-up or non-cases, and the RRs with the variance estimates for at 
least three quantitative categories of GGT levels are known. The median or mean level of GGT 
for each category was assigned to each corresponding RR. If data were not available, we 
estimated the median using the midpoint of each category. When the highest or lowest category 
was open, we assumed it to be the same amplitude as the adjacent category. In the first stage, as 
described by Orsini et al,[24] a restricted cubic spline model with 2 spline transformations (3 
knots minus 1) was estimated using generalized least-squares regression taking into account the 
correlation within each set of published RRs. In the second stage, the 2 regression coefficients 
and the variance/covariance matrix that had been estimated within each study were combined 
using the restricted maximum likelihood method in a multivariate random-effects meta-
8 
 
 
 
analysis.[26] A P value for nonlinearity was calculated by testing that the coefficient of the 
second spline was equal to zero.[27] 
 
Statistical heterogeneity across studies was quantified using Cochran χ
2
 and the I
2 
statistics.[28, 
29] Study-level characteristics including geographical location, sex, average age at baseline, 
average duration of follow-up, number of cases, case definition for hypertension, degree of 
adjustment, and study quality were pre-specified as characteristics for assessment of 
heterogeneity, which was conducted using stratified analysis and random effects meta-
regression.[30] We assessed the potential for small study effects such as publication bias 
through formal tests, namely Begg’s funnel plots[31] and Egger’s regression symmetry test.[32] 
Finally, we adjusted for the effect of publication bias by the use of the Duval and Tweedie’s 
nonparametric trim-and-fill method.[33] All analyses were conducted using Stata version 13 
(Stata Corp, College Station, Texas).   
 
RESULTS 
Study identification and selection 
Our initial search identified 612 potentially relevant citations (Figure 1). After screening the 
titles and abstracts, 23 articles remained for further evaluation. We reviewed and assessed these 
23 articles, and excluded 9 articles because (i) they had no relevant outcome (n = 6) (ii) they 
were not prospective (n = 2) or duplicated a previous publication using the same cohort (n = 1). 
In sum, this meta-analysis included 14 articles (Supplementary Material 5) based on 14 
unique prospective cohort studies comprising 44,582 participants and 5,270 hypertension cases. 
 
Study characteristics and quality 
Table 1 provides details of the eligible studies. The mean age of participants at baseline ranged 
from approximately 25 to 62 years. One study included participants aged 15 years and over, 
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however, participants who were less than 18 years comprised only 9.3% of the total sample.[34] 
Two studies included participants from Europe (France and Turkey), two from North America 
(United States), nine from Asia (South Korea, Hong Kong, Japan, and China), and one from 
Australia. Duration of follow-up to the development of hypertension ranged from 3 to 15 years. 
Studies ascertained the diagnosis of hypertension (or high blood pressure) using the following 
definitions: blood pressure ≥ 130/85 mmHg, 140/90 mmHg, 160/95 mmHg and/or taking 
antihypertensive medication. All studies evaluated the associations in approximately general 
healthy populations with the exception of one study which was conducted among 
prehypertensive adults.[35] The degree of covariate adjustment varied, but majority of studies 
adjusted for potential risk factors for hypertension such as age, body mass index, smoking 
status, exercise, and alcohol consumption, with three additionally adjusting for another liver 
enzyme or inflammatory markers. Two studies adjusted for only age. An unadjusted estimate 
was calculated for one study. Overall, we judged all of the included studies to be of adequate 
quality (quality score: 6-9). One study scored 9 points, four studies scored 8 points, seven 
studies scored 7 points, and two studies scored 6 points. Supplementary Material 6 provides 
assay characteristics of measured levels of GGT from studies contributing to the analysis. Apart 
from 7 studies which did not provide specific details of type of assays used for GGT 
measurements, all other studies employed the enzymatic colorimetric method which has been 
shown to be precise for detecting GGT activity.[36] As reported in Supplementary Material 6, 
the majority of studies assessed the associations within normal reference ranges of GGT. 
 
Association of GGT and hypertension 
The pooled RR (95% CI) of hypertension in a comparison of individuals in the top thirds with 
those in the bottom thirds of baseline GGT level for all 14 studies was 1.32 (1.23-1.43) (Figure 
2). The combined RR excluding the study which was conducted among participants with 
prehypertension was 1.31 (1.22-1.42), which was similar to the main finding. Similarly, the 
pooled RR was 1.26 (1.18-1.35) on excluding the study with an unadjusted estimate and 1.30 
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(1.21-1.40) on excluding the study that included participants aged 15 years and over. The 
pooled RR was minimally attenuated on simultaneously excluding all three studies 1.23 (1.15-
1.31). On simultaneous exclusion of the study with an unadjusted estimate and studies that 
presented only age-adjusted estimates, the pooled RR was attenuated but not significantly 
altered 1.08 (1.02-1.13). There was substantial heterogeneity between studies (I2>70%), which 
was partly explained by study level characteristics such as age at baseline (P for meta-regression 
= 0.007), average follow-up duration (P for meta-regression = 0.04), and degree of adjustment 
(P for meta-regression < 0.0001) (Supplementary Material 7). A stronger association was 
observed in studies that included older participants (≥ 45 years) compared to studies with 
younger participants (< 45 years) and studies with a longer duration of follow-up (≥ 5 years) 
compared to studies with shorter duration of follow-up (< 5 years). In further subgroup analysis 
(data not shown), a stronger association was observed in Asian studies 2.16 (1.47-3.19) 
compared to other populations 1.53 (1.12-2.10) (P for meta-regression = 0.293). Egger’s test 
was significant (P = 0.001), consistent with observed funnel plot asymmetry (Supplementary 
Material 8), suggesting that studies with less striking results were less likely to have been 
reported. Despite the concern that small studies with null results often tend not to be published, 
we found no definitive evidence of such selective reporting when studies were grouped by size 
in meta-regression analysis (Supplementary Material 7). Duval and Tweedie’s trim-and-fill 
method identified 7 missing studies and addition of these hypothetical missing studies did not 
alter the significant association between GGT and hypertension risk, although substantially 
weaker (pooled RR comparing top versus bottom third, 1.11: 1.02-1.20). 
 
Dose-response analysis 
In pooled analysis of 10 studies (total of 13 data points because results for males and females 
were reported separately for some of the studies) providing relevant data, we found no evidence 
of statistically significant departure from linearity (P for nonlinearity =0.37) between GGT 
levels and risk of hypertension, which was present across the spectrum of GGT values (4.5-54.5 
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U/L) in our study. Visual inspection of the plot was also consistent with a linear shape (Figure 
3).  The combined RR (95% CI) of hypertension for a 5 U/L increment in GGT level was 1.08 
(1.04-1.13).  
 
DISCUSSION 
Unlike the previous elegant review by Liu and colleagues,[15]  who presented a pooled estimate 
for hypertension comparing the highest versus lowest category of GGT levels irrespective of the 
risk comparisons reported by the included studies;  the present meta-analysis provides a more 
precise estimate of the magnitude of the association between baseline circulating GGT and 
incident hypertension. Comparing individuals in the top versus bottom thirds of circulating 
GGT levels, our results show an approximately 30% increased risk of future hypertension in 
pooled analysis of 14 variably adjusted eligible studies. The risk was attenuated to 8% in pooled 
results of only studies that adjusted for established risk factors and/or other potential 
confounders. The observed heterogeneity among the studies seemed to be explained by average 
age of participants at baseline, average duration of follow-up, and the degree of confounder 
adjustment. There were more extreme results in studies conducted among older individuals, 
consistent with established evidence that increasing age is associated with a significant increase 
in the incidence of hypertension or high BP. As expected, a stronger association with longer 
follow-up duration was also demonstrated. A stronger association was observed in Asian 
populations compared to Western populations (though P-value for meta-regression > 0.05), 
consistent with findings from the previous review[15] and the fact that liver diseases and 
metabolic syndrome (strongly associated with hypertension or high BP) are very prevalent in 
Asians. A stronger association was also observed in males compared to females (though P-value 
for meta-regression > 0.05); which is consistent with the significant gender differences in GGT 
levels, with males having higher levels than females.[37] In addition, males are more likely to 
develop cardiometabolic diseases at lower average levels of risk markers such as body mass 
index,[38] which is also causally associated with GGT levels.[39] However, in the context of 
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the greater proportion of studies featuring more male than female participants in our review, 
these findings should be interpreted with caution. Our study also provides for the first time, a 
detailed assessment of the dose-response nature of the association between circulating GGT 
level and risk of hypertension. The findings were consistent with a linear dose-response 
relationship, which was characterised by an 8% increase in the risk of hypertension for every 5 
U/L increment in circulating GGT level.  
 
Possible explanations for findings 
A large body of evidence has shown that GGT is positively and independently associated with 
cardiovascular disease (CVD) risk and in a linear fashion.[10, 40] Several mechanistic pathways 
postulated for this association include oxidative stress, increased inflammation, and underlying 
fatty liver. [41] These same pathways have also been implicated in the relationship between 
GGT and risk of hypertension. Elevations of serum hepatic enzymes including GGT, have been 
linked to the development and progression of fatty liver with increasing body mass index.[42] 
Elevated GGT levels are also suggested to signify oxidative stress and a state of chronic 
inflammation. [43] The states of oxidative stress, increased inflammation, and fatty liver may 
impair insulin signalling in the liver, leading to impaired insulin secretion and insulin resistance, 
which have been implicated in the development of hypertension or high BP. [12, 14]  
 
Implications of findings 
Our findings are relevant as they provide further insight concerning the relationship between 
baseline circulating GGT levels and risk of hypertension and may also have implications for the 
prevention of hypertension or high BP. Though the cut-off value and reference range for GGT 
has not been clearly defined, and is essentially arbitrary, being determined ideally by enzyme 
measuring activity in a healthy population and using the central 95% of values obtained from 
the population;[44] the recommended cut-off for the upper normal limit of GGT is set at an 
average of 51 U/L for men and 33 U/L for women.[45] Consistent with the large body of 
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evidence suggesting an increased risk of adverse cardiometabolic outcomes at GGT levels 
considered to reflect normal reference ranges,[8, 9, 40] our findings also underscore a 
potentially deleterious role of increasing GGT levels within the normal range on future risk of 
hypertension in general population settings. Lifestyle measures such as salt restriction, 
moderation of alcohol consumption, high consumption of vegetables and fruits and low-fat, 
maintaining a healthy body weight, regular physical exercise, and elimination of smoking been 
recommended as the cornerstone for the prevention of hypertension in non-hypertensive 
individuals.[7] Given that serum GGT levels can be considerably reduced by most of these 
lifestyle interventions,[46] which also affect levels of established risk factors for hypertension; 
there remains a possibility that lowering or modification of serum levels of GGT may help in 
hypertension prediction or prevention. Further evaluation is warranted.  
 
Strengths and limitations 
The strengths and limitations of this meta-analysis merit careful consideration. The notable 
strengths include our ability to transform reported risk estimates from all contributing studies to 
a consistent comparison (top versus bottom thirds) to allow a consistent combination of 
estimates across studies, therefore obtaining a reliable estimate of the magnitude of the 
association and enhancing interpretation of the overall findings. We have also provided a 
detailed assessment of the dose-response relationship between GGT and risk of hypertension, 
which has not been previously demonstrated. We systematically explored and identified the 
possible sources of heterogeneity using stratified analyses and meta-regression. Formal tests 
demonstrated evidence of publication bias, suggesting that studies with less striking results were 
less likely to have been reported. However, there was no clear evidence of such selective 
reporting when studies were grouped by size. A detailed quality assessment of eligible studies 
was performed, with all included studies attaining moderate to high quality scores. Our main 
weakness was the inability to fully examine the impact of adjustment for potential confounding 
factors, because the review was based on variably adjusted data reported in the published 
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literature. However, majority of included studies adjusted for major potential confounders 
(including alcohol consumption which is known to increase serum levels of GGT) of the GGT-
hypertension association and grouping the studies by degree of adjustment did not appreciably 
alter the direction of the association. In addition, the dose-response analysis was based on data 
points from ten out of the 14 eligible studies, as the investigators concerned did not respond to 
our request for additional data or could not be contacted at all. Finally, it was not possible to 
correct the estimates for within-individual variation in levels of GGT, because the included 
studies lacked serial assessments of circulating levels of this exposure in the same individuals. 
 
Conclusions 
Circulating level of GGT is associated with an increased risk of hypertension in the general 
population, consistent with a linear dose-response relationship. Further investigation of any 
potential relevance of GGT in hypertension prevention is warranted. 
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Figure legends 
 
Figure 1. Selection of studies included in the meta-analysis 
612 Potentially relevant citations identified
From MEDLINE, EMBASE, Web of Science, 
and reference list of relevant studies
589 excluded on the basis of title 
and/ or abstract
9 Articles excluded due to:
6 No relevant outcome 
2 Cross-sectional designs
1 Overlapping participants
14 Articles included, based on 14 
unique studies
23 Full-text articles retrieved for more 
detailed evaluation
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GGT, gamma-glutamyltransferase. 
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Figure 2. Relative risks for hypertension in individuals in the top compared to the bottom third 
of baseline levels of gamma-glutamyltransferase in eligible studies 
Overall
Onat, 2011
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The summary estimate presented was calculated using a random effects model; †, Degree of 
adjustment: +, unadjusted or adjusted for age and/ or sex; ++, further adjustment for potential 
hypertension risk factors; +++, additional adjustment for other liver markers or inflammatory 
markers; Size of data markers are proportional to the inverse of the variance of the relative ratio; 
CI, confidence interval (bars); GGT, gamma-glutamyltransferase; RR, relative risk 
 
Risk comparisons originally reported by the eligible studies are as follows: Yamada 1991, 
reported number of hypertension cases by GGT categories (≥ 50 and < 50 U/L); Miura 1994, 
user-defined cut-offs; Li 2015, estimates provided by authors; Cheung 2011, tertiles; Hwang 
2010, quartiles; Kim 2012, quartiles; Jo 2009, quartiles; Stranges 2005, quintiles; Onat 2011, 
per standard deviation change; Xu 2011, quartiles; Andre 2007, quartiles; Jimba 2009, tertiles; 
Lee 2003, user-defined cut-offs; and Lee 2002, user-defined cut-offs 
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 Figure 3. Dose-response relation between gamma-glutamyltransferase levels and relative risk 
of hypertension for pooled results of studies providing relevant data 
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Adjusted relative risks and 95% confidence intervals (CIs; dashed lines) are reported. GGT 
levels were modeled with restricted cubic splines with 3 knots. Lines with long dashes represent 
the pointwise 95% confidence intervals for the fitted linear trend (solid line). Lines with short 
dashes represent the linear trend. The vertical axis is on a log scale; GGT, gamma-
glutamyltransferase 
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Table 1. Characteristics of published prospective studies evaluating associations between gamma-glutamyltransferase and incident hypertension 
 
Lead author, 
publication year 
 
Name of study or 
source of 
participants 
 
Location 
of study 
 
Year(s) of 
baseline 
survey 
 
Baseline mean age  
(age range), years 
 
% 
male 
 
Duration of 
follow-up 
 
Total no. of 
participants 
 
No. of 
cases 
 
 
Hypertension case definition 
 
 
Covariates adjusted for 
 
Study 
quality 
            
Yamada, 1991 Metal Products Factory Japan 1983 43.0 (35-54) 100.0 5.0 1,393 29 SBP ≥ 160 mmHg, DBP ≥ 95 
mmHg 
Unadjusted 6 
Miura, 1994 Rural community Japan 1979-1980 47.8 (30-69) 100.0 10.0 77 36 SBP≥140 mmHg, DBP ≥ 90 
mmHg, or taking antihypertensive 
medication 
Age, SBP, DBP, alcohol consumption 8 
Lee, 2002 Steel Manufacturing 
Company  
South 
Korea 
1994; 1998 NS (25-50) 100.0 4 8,170 169 SBP ≥ 160 mmHg, DBP ≥ 95 
mmHg, and/or taking 
antihypertensive medication 
Age, BMI, smoking (pack years), drinking, 
exercise, family history of hypertension, SBP 
or DBP, changes of BMI, drinking during four 
years 
7 
Lee, 2003 CARDIA USA 1985-1986 25.0 (18-30) NS 15.0 4,704 708 SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg, or taking antihypertensive 
medication 
Study center, race, sex, age, alcohol 
consumption, BMI, smoking, PA, fasting 
serum glucose, insulin for diabetes, SBP, 
insulin for hypertension 
8 
Stranges, 2005 WNYS USA 1986-2001 NS (39-79) 65.4 6.0 897 195 SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg, or taking 
antihypertensive medication 
Age, gender, race, average amount of alcohol, 
smoking status, BMI, PA, SBP 
7 
Andre, 2007 DESIR France 1994-1996 46.0 (30-65) 55.2 3.0 1,776 377 SBP  ≥ 130 mmHg, DBP ≥ 85 
mmHg or treatment of previously 
diagnosed hypertension 
Age 7 
Jo, 2009 HPC South 
Korea 
2002 38.7 (19-86) 70.8 4.0 17,281 2,170 SBP ≥ 130 mmHg, DBP ≥ 85 
mmHg, or taking antihypertensive 
medication 
Age 6 
Jimba, 2009 SSK Hospital Japan 2002-2003 49.0 (NS) NS 3.0 1,027 288 SBP ≥ 130 mmHg, DBP ≥ 85 
mmHg, or taking antihypertensive 
medication 
Age, sex, alcohol habits, BMI at baseline 7 
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Lead author, 
publication year 
 
Name of study or 
source of 
participants 
 
Location 
of study 
 
Year(s) of 
baseline 
survey 
 
Baseline mean age  
(age range), years 
 
% 
male 
 
Duration of 
follow-up 
 
Total no. of 
participants 
 
No. of 
cases 
 
 
Hypertension case definition 
 
 
Covariates adjusted for 
 
Study 
quality 
Hwang, 2010 Community South 
Korea 
2003 54.1 (> 30) 39.2 5.0 293 83 SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg, or taking antihypertensive 
medication 
Age, education, BMI, alcohol intake, smoking, 
exercise, salt intake, family history of 
hypertension, ALT 
7 
Cheung, 2011 CRISPS-2 Hong 
Kong 
2005-2008 47.3 (25-75) 39.5 5.3 708 126 SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg, or taking antihypertensive 
medication 
Age, sex, SBP at baseline and follow-up 
duration, baseline BMI, HDL-C, HOMA-IR, 
CRP, fibrinogen, current smoking, change in 
BMI 
9 
Onat, 2011 TARFS Turkey 2003-2004 52.0 (33-84) 49.1 4.0 1,422 476 SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg, or taking antihypertensive 
medication 
Age, sex, menopause, BMI, alcohol use 8 
Xu, 2011 Shangai China 2004-2008 NS (≥ 40) 60.2 3.5 285 119 SBP>=130 mmHg, DBP>=85 
mmHg, or taking antihypertensive 
medication 
Age and sex 7 
Kim, 2012 Kangbuk Samsung 
Hospital 
South 
Korea 
2002-2005 44.0 (NS) 67.9 3.0 4,783 389 SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg, or taking antihypertensive 
medication 
Age, sex, alcohol amount, smoking status, PA, 
baseline glucose, uric acid, HDL-C, LDL-C, 
TG, hsCRP, SBP 
8 
Li, 2015 Rural indigenous 
community 
Australia 1997-2008 31.4 (15-78) 41.0 6.6 1,766 100 SBP ≥ 140 mmHg, DBP ≥ 90 
mmHg, or taking antihypertensive 
medication 
Age, sex, ethnicity, abdominal obese, PA, 
diabetes, dyslipidemia 
7 
Total       44,582 5,270    
CARDIA, Coronary Artery Risk Development in Young Adults; CRISPS-2, Cardiovascular Risk Factor Prevalence Study; DESIR, Data from Epidemiological Study on the Insulin Resistance Syndrome; HPC, Health Promotion 
Centre; SSK, Saitama-ken Saiseikai Kurihashi; TARFS, Turkish Adult Risk Factor Study; WNYS, Western New York Health Study;  
ALT, alanine aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin 
resistance; LDL-C, low density lipoprotein cholesterol; NS, not stated; PA, physical activity; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides 
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Supplementary Material 1: PRISMA 2009 check-list 
 
Section/topic 
Item 
No Checklist item 
Reported on page 
No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, 
interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review 
registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 4 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and 
study design (PICOS) 
5 
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration 
information including registration number 
None 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, 
publication status) used as criteria for eligibility, giving rationale 
5-6 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in 
the search and date last searched 
5-6 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated Supplementary 
Material 3 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis) 
6-7 
Data collection process 10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators 
6-7 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made 7 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data synthesis 
7-8 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). 7-8 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistic) 
for each meta-analysis 
8-9 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within 
studies) 
8-9 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre- 8-9 
26 
 
 
 
Section/topic 
Item 
No Checklist item 
Reported on page 
No 
specified 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally 
with a flow diagram 
9 and Figure 1 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the 
citations 
9-10, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). 10, Table 1 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) 
effect estimates and confidence intervals, ideally with a forest plot 
10-11, Figure 2 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency 10-11, Figure 2 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) 10-11, Supplementary 
Material 7-8 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see item 16) 11, Supplementary 
Material 7 
Discussion 
Summary of evidence 24 Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as 
health care providers, users, and policy makers) 
11-12 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified 
research, reporting bias) 
13 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research 13 
Funding 
Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic 
review 
None 
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Supplementary Material 2: MOOSE checklist  
 
 
Gamma-glutamyltransferase and risk of hypertension: a systematic review and dose-
response meta-analysis of prospective evidence 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
√ Problem definition Elevated baseline circulating gamma-glutamyltransferase (GGT) has 
been demonstrated to be strongly associated with risk of hypertension 
or high blood pressure (BP), but the precise magnitude of the 
association and nature of the dose-response relationship is uncertain 
√ Hypothesis statement There is a linear dose-response relationship between GGT level and 
risk of hypertension 
√ Description of study outcomes Hypertension 
√ Type of exposure  Blood levels of GGT 
√ Type of study designs used Prospective (cohort, case-cohort or “nested case control”) population-
based studies 
√ Study population Approximately general populations (i.e., did not select participants on 
the basis of confirmed pre-existing medical conditions such as 
hypertension, cardiovascular disease, liver disease, or chronic kidney 
disease at baseline).  
Reporting of search strategy should 
include 
 
√ Qualifications of searchers Setor Kunutsor, MD PhD; Tanefa A. Apekey, PhD 
√ Search strategy, including time 
period included in the synthesis and 
keywords 
Time period: from inception of MEDLINE, EMBASE, Web of 
Science to May 2015.  
Search strategy: 
1 (Gamma glutamyltransferase”[MeSH] OR "gamma 
glutamyltransferase"[All Fields]) 
2 ("Hypertension"[MeSH] OR "Blood pressure"[All Fields]) 
3 ("humans"[MeSH Terms]) 
4 (1 AND 2 AND 3) 
 
√ Databases and registries searched MEDLINE, EMBASE, and Web of Science 
√ Search software used, name and 
version, including special features 
Ovid was used to search EMBASE 
Reference Manager used to manage references  
√ Use of hand searching We searched bibliographies of retrieved papers  
√ List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  
The citation list for excluded studies is available upon request. 
√ Method of addressing articles 
published in languages other than 
English 
We placed no restrictions on language 
√ Method of handling abstracts and 
unpublished studies 
None found 
√ Description of any contact with 
authors 
We contacted authors who did not report relative risks with 95% 
confidence intervals for at least three quantitative categories of GGT 
or a linear dose-response trend 
Reporting of methods should include  
√ Description of relevance or 
appropriateness of studies assembled 
for assessing the hypothesis to be 
tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
√ Rationale for the selection and 
coding of data 
Data extracted from each of the studies were relevant to the 
population characteristics, study design, exposure, outcome, and 
possible effect modifiers of the association. 
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√ Assessment of confounding We assessed confounding by ranking individual studies on the basis 
of different adjustment levels, and performed sub-group analyses to 
evaluate differences in the overall estimates according to levels of 
adjustment. 
√ Assessment of study quality, 
including blinding of quality 
assessors; stratification or regression 
on possible predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa 
Scale using pre-defined criteria namely: population 
representativeness, comparability (adjustment of confounders), 
ascertainment of outcome. Sensitivity analyses by several quality 
indicators such as study size, duration of follow-up, and adjustment 
factors. 
√ Assessment of heterogeneity Heterogeneity of the studies was explored with I2 statistic that 
provides the relative amount of variance of the summary effect due to 
the between-study heterogeneity. 
√ Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses, sensitivity analyses, meta-
regression and assessment of publication bias are detailed in the 
methods. We performed random effects meta-analysis with Stata 13. 
√ Provision of appropriate tables and 
graphics 
Table 1, Figures 1-3, Supplementary Materials 7-8 
Reporting of results should include  
√ Graph summarizing individual study 
estimates and overall estimate 
Figure 2 
√ Table giving descriptive information 
for each study included 
Table 1 and Supplementary Material 6 
√ Results of sensitivity testing 
 
Sensitivity analysis was conducted to assess the influence of each 
individual study by omitting one study at a time and calculating a 
pooled estimate for the remainder of the studies. Results section 
√ Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates, 
I2 values and results of sensitivity analyses 
Reporting of discussion should include  
√ Quantitative assessment of bias Sensitivity analyses indicate heterogeneity in strengths of the 
association due to most common biases in observational studies. 
Limitations have been discussed. 
 
√ Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria 
in methods section. 
√ Assessment of quality of included 
studies 
Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
√ Consideration of alternative 
explanations for observed results 
Discussed in the context of the results. 
√ Generalization of the conclusions Discussed in the context of the results. 
√ Guidelines for future research Assessment of the potential utility of GGT in prediction of 
hypertension  
√ Disclosure of funding source No separate funding was necessary for the undertaking of this 
systematic review. 
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Supplementary Material 3: Literature search strategy 
 
Relevant studies, published before May 20, 2015 (date last searched), were identified through 
electronic searches not limited to the English language using MEDLINE, EMBASE, and the Science 
Citation Index databases. Electronic searches were supplemented by scanning reference lists of articles 
identified for all relevant studies (including review articles), by hand searching of relevant journals and 
by correspondence with study investigators. The computer-based searches combined search terms 
related to gamma-glutamyltransferase and hypertension without language restriction. 
 
(i) MEDLINE strategy to identify relevant exposures: 
(“Gamma glutamyltransferase”[MeSH] OR "gamma glutamyltransferase"[All Fields] OR "Gamma 
glutamyltranspeptidase"[MeSH] OR "gamma glutamyltranspeptidase"[All Fields]) 
 
(ii) MEDLINE strategy to identify relevant outcomes: 
("Hypertension"[MeSH] OR “hypertension”[All Fields] OR "Blood pressure"[MeSH] OR “blood 
pressure”[All Fields])  
 
(iii) MEDLINE strategy to identify relevant population: 
("humans"[MeSH Terms]) 
 
Parts i, ii and iii were combined using ‘AND’ to search MEDLINE. Each part was specifically 
translated for searching alternative databases. 
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Supplementary Material 4: Risk conversion method 
 
To enable a consistent approach to the meta-analysis and enhance interpretation of findings, relative risk estimates 
for association of gamma-glutamyltransferase (GGT) and hypertension or high blood pressure (BP) that were 
often differently reported by each study [e.g. per unit or standard deviation (SD) change, quintiles, quartiles, or 
other groupings] were transformed to involve comparisons between the top third and bottom third of each study 
population’s baseline distribution of GGT levels using standard statistical methods.1,2 Briefly, assuming a 
normally distributed exposure (e.g. log GGT) with a log-linear association with hypertension risk (i.e. linear 
relationship between log relative risk estimates and levels of the exposure), conversion factors to convert log 
relative risks from reported scale comparisons to top versus bottom third comparisons are derived based on the 
ratio of expected differences in mean levels of the standardised exposure (i.e. SD scale), for the target comparison 
versus reported comparison. For example, the expected difference in means of the top versus bottom thirds of the 
standard normal distribution is 2.18 SDs, 2.54 SDs for the top versus bottom quartile, and 2.80 SDs for the top 
versus bottom quintile. Hence, relative risk estimates reported for comparisons of extreme quartiles can be 
converted to comparisons of extreme thirds by applying a multiplication conversion factor of 2.18/2.54 to the log 
relative risk and its standard error and estimates reported for comparisons of extreme quintiles can be converted to 
comparisons of extreme thirds by applying a multiplication conversion factor of 2.18/2.80 to the estimates. 
Similarly, estimates reported per 1 SD can be multiplied by 2.18 to obtain the top versus bottom third comparison, 
and those reported per unit change can be multiplied by 2.18*SD of exposure, to obtain similar comparison. 
Conversion factors for other possible reported comparisons are derived similarly. The method has been generally 
been implemented in Stata function --riskconv-- available from  
http://www.phpc.cam.ac.uk/ceu/research/erfc/stata/3 and has been used in previous numerous published meta-
analyses.4-6 
 
 
 
1. Chêne, G and Thompson, SG. Methods for Summarizing the Risk Associations of Quantitative Variables 
in Epidemiologic Studies in a Consistent Form. American Journal of Epidemiology. 1996;144:610-621 
2. Greenland, S and Longnecker, MP. Methods for trend estimation from summarized dose-response data, 
with applications to meta-analysis. American Journal of Epidemiology. 1992;135:1301-1309. 
3. The Emerging Risk Factors Collaboration. ERFC Methods. Accessed at 
http://www.phpc.cam.ac.uk/ceu/research/erfc/methods/ on 26 February 2014. 
4. Thompson A and Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the 
apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective 
studies. J Intern Med. 2006;259:481-492 
5. Chowdhury R, Stevens S, Gorman D, Pan A, Warnakula S, Chowdhury S et al. Association between fish 
consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and 
meta-analysis. BMJ. 2012;345:e6698. 
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Supplementary Material 6: Study and assay characteristics of studies contributing data to current analysis 
 
Lead Author, 
publication 
year 
Name of study or 
source of participants 
Sampling 
method 
Sample 
source 
Fasting 
samples 
Sample state before 
analysis, storage, 
temperature(°C) if 
frozen 
 
 
Reference ranges (mean GGT 
levels) in study, U/L* 
 
 
Assay method 
Assay source 
(Manufacturer) 
Yamada, 1991 Metal Products Factory Complete Serum NS Fresh 
NS (24.7) 
NS 
Automatic analyzer (SMAC III, Technicon, 
Tarrytown, N.Y.) 
Miura, 1994 Rural community Complete Serum NS NS 
NS (17.5) L-gamma-glutamyl-p-nitroanilide 
used as substrate 
Automatic analyser (Hitachi-716, Hitachi, Tokyo) 
Lee, 2002 
Steel Manufacturing 
Company 
Complete Serum Yes Fresh 
0-49 (NS) 
NS 
Automatic analyser (normal 
range 0–50 U/L; Hitachi 7170, Japan) 
Lee, 2003 CARDIA Complete Serum NS Frozen, -70 
NS (NS) 
NS 
SMA-CII continuous-flow analyzer (Technicon 
Instruments Corp.) 
Stranges, 2005 WNYS Complete Serum Yes Fresh 
NS (22.4) 
Kinetic method Paramax Automated Chemistry System 
Andre, 2007 DESIR Complete Serum Yes Fresh 
Men: < 30 (37.1) 
Women: < 24 (20.9) NS Technicon DAX 
Jo, 2009 HPC Complete Serum Yes NS 
Men: (36.4) 
Women: (13.5) 
Modified Szasz 
method 
ADVIA 1650 auto-analyzer (Siemens, Tarrytown 
NY) 
Jimba, 2009 SSK Hospital Complete NS Yes NS 
12-58 (47.0) 
l-γ-glutamyl-p-nitroanilide method NS 
Hwang, 2010 Community Complete NS NS NS 
NS (Median, 16.0) 
NS NS 
Cheung, 2011 CRISPS-2 Random Plasma Yes NS NS (20.5) NS Hitachi 912 analyzer 
Onat, 2011 TARFS Complete Serum Yes Frozen, -75 
Men: < 50 (Median, 24.9) 
Women: < 30 (Median, 17.0) 
Kinetic method Hitachi 902 Autoanalyzer 
Xu, 2011 Shangai Complete Serum Yes NS 
NS (Range, 12-68) 
NS 
Autoanalyser (CX-7 Biochemical Autoanalyser; 
Beckman Coulter, BREA, CA, USA 
Kim, 2012 
Kangbuk Samsung 
Hospital 
Complete Serum Yes NS 
Men: 0-51  (25.8) 
Women:0-51  (13.3) Kinetic spectrophotometric method 
Autoanalyzer (Adiva 1800, Siemens Healthcare 
Diagnostics, Tokyo, Japan) 
Li, 2015 
Rural indigenous 
community 
Complete Plasma Yes Fresh 
Men: NS (56.0) 
Women: NS (27.5) Kinetic spectrophotometric method 
Cobas Integra 800 (Roche Diagnostics, New York, 
USA) 
Study acronyms are provided in Table 1; Reference list of included studies in Supplementary Material 5; GGT, gamma-glutamyltransferase; NS, not stated; *, values in parenthesis are mean values unless otherwise 
stated. 
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Supplementary Material 7: Relative risks for hypertension in individuals in the top versus 
bottom thirds of baseline levels of gamma-glutamyltransferase, grouped according to several 
study characteristics 
 
Male
≥ 45
Europe
BP ≥ 130/85 mmHg
Sex
BP ≥ 140/90 mmHg
< 8
≥ 8
No. of cases
≥ 5
≥ 250
Study quality
North America
++
Degree of adjustment
+++
Average follow up, years
< 250
Definition of hypertension
Age at baseline, years
BP ≥ 160/95 mmHg
+
< 45
Female
Group
< 5
Location
Asia-Pacific
Both
1,975
1,705
858
2,959
2,113
3,535
1,735
1,277
4,413
903
1,972
598
No. of
857
198
2,700
3,565
894
Cases
3,993
3,509
2,401
2.15 (1.24, 3.72)
1.64 (1.32, 2.02)
1.48 (1.26, 1.73)
1.55 (1.20, 1.99)
2.01 (1.41, 2.86)
1.91 (1.35, 2.72)
1.76 (1.19, 2.62)
2.80 (1.42, 5.56)
1.46 (1.05, 2.02)
1.27 (0.75, 2.17)
1.05 (1.00, 1.09)
2.52 (1.68, 3.77)
2.57 (1.40, 4.70)
2.76 (0.37, 20.58)
2.27 (1.38, 3.74)
1.23 (1.14, 1.33)
1.74 (1.05, 2.87)
RR (95% CI)
1.46 (1.07, 1.99)
2.25 (1.55, 3.27)
1.63 (1.22, 2.18)
0.757
0.007
0.312
0.487
0.925
0.040
0.070
< 0.0001
P-value*
1.5 2.5 5 7.5 15 25
RR (95% CI)  top versus bottom third of baseline GGT level
 
The summary estimates presented were calculated using random effects models; Size of data markers 
are proportional to the inverse of the variance of the relative ratio; BP, blood pressure; CI, confidence 
interval (bars); GGT, gamma-glutamyltransferase; RR, relative risk; *, P-value for meta-regression 
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Supplementary Material 8: Assessment of small study effects by funnel plot and Egger’s test 
Lee, 2002, 3
Jimba, 2009
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Onat, 2011
Stranges, 2005
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Kim, 2012
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Li, 2015
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Study references are provided in Supplementary Material 5. The dotted lines show 95% confidence 
intervals around the overall summary estimate calculated using a fixed effect model; GGT, gamma-
glutamyltransferase; P-value for bias calculated using Egger’s test was 0.001 
 
 
